FLAGSHIP PIONEERING
In January 2025, the Milner Therapeutics Institute launched a partnership with Flagship Pioneering and Cambridge University Health Partners (CUHP). It was the first Flagship partnership in Europe, reflecting their vision to work more extensively in the UK following the establishment of Quotient Therapeutics here in Cambridge. The collaboration brought together Flagship’s ecosystem of more than 40 companies with Cambridge researchers and clinicians, with a shared ambition to accelerate therapeutic research and innovation.
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.
